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a b s t r a c t 
Background: Little is known about rates of access site (transradial (TRI) or transfemoral (TFI)) preference 
for percutaneous coronary intervention (PCI) and in-hospital costs of patients undergoing these proce- 
dures in lower-and middle-countries. Here, we report on access site use, in-hospital costs and outcomes 
of patients undergoing PCI in Vietnam. 
Methods: Information from 868 patients were included in the cohort of 1022 patients recruited into the 
first PCI registry in Vietnam. The total hospital costs and in-hospital outcomes of patients undergoing TRI 
and TFI were compared. Hospital costs were obtained from the hospital admission system, and major ad- 
verse cardiac events, major bleeding events and length of stay were identified through review of medical 
records. 
Findings: TRI was the dominant access site for interventionists (694/868 patients). The TFI group re- 
ported more lesions of the left main artery, more previous coronary artery bypass grafts and previous 
PCI in comparison with the TRI group (all p < 0.05). The TRI group was associated with a lower overall 
cost of admission (the adjusted difference was -1526.3 USD, 95% confident interval CI (-1996.2; -1056.3), 
shorter length of hospital stay (-2 days, CI (-2.8; -1.2)) and lower rates of major bleeding post-procedure. 
Procedural factors such as radial access site, left main disease, PCI ≥2 stents, and PCI ≥ 2 lesions having 
the most impact on the in-hospital cost of patients undergoing PCI. 
Interpretations: Among patients undergoing PCI, TRI was associated with lower costs and favourable clin- 
ical outcomes relative to TFI 
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This is an open access article under the CC BY-NC-ND license 








Abbreviations: BARC, Bleeding Academic Research Consortium; CABG, Coronary 
rtery bypass grafts; CHD, Coronary heart disease; LOS, Length of stay; MACE, Major 
dverse cardiac event; PCI, Percutaneous coronary intervention; TFI, Transfemoral 
ntervention; TRI, Transradial intervention; VNHI, Vietnam National Heart Institute. 
✩ The authors report no relationships that could be construed as a conflict of in- 
erest. 
∗ Corresponding author at: Thai Nguyen University of Medicine and Pharmacy, 
hai Nguyen, Vietnam. 
E-mail address: hoavu1086@gmail.com (H.T.T. Vu). 
ttps://doi.org/10.1016/j.lanwpc.2021.100116 
666-6065/© 2021 The Authors. Published by Elsevier Ltd. This is an open access article uResearch in context 
• Evidence before this study: Choosing the optimal access 
location for percutaneous coronary intervention (PCI) has 
been controversial for many years. Despite accumulat- 
ing studies on the differences between trans-radial access nder the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 




































































































(TRI) and trans-femoral access (TFI), data addressing the 
cost difference between TRI and TFI is scarce. Few num- 
bers of previous studies conducted largely in high-income 
countries reported using TRI is low-cost relative to TFI. 
While the use of PCI is of growing interest in Asia, the 
impact of PCI access site on hospital cost has not been 
clearly understood in this region. 
• Added value of this study: Based on a pilot PCI registry in 
Vietnam, this study provides the first insight into the cost 
and outcome differences between TRI and TFI and iden- 
tified factors associated with hospital cost of PCI patients 
in a low and middle-income country. 
• Implications of all the available evidence: In low-resource 
settings, TRI is likely a choice of cardiologists to perform 
PCIs due to its cost savings and favourable clinical out- 
comes compared with TFI. The findings may help inform 
clinical practice and fill the gap in the literature on PCI 
cost in developing countries. 
. Introduction 
Percutaneous coronary intervention (PCI) has been recognized 
s an effective treatment for individuals with coronary heart dis- 
ase (CHD). While transfemoral access (TFI) is the traditional ap- 
roach in cardiac catheterization, the use of transradial access (TRI) 
as grown significantly in the last two decades [1] . A number 
f randomized clinical trials and literature reviews have demon- 
trated favourable cardiac outcomes, shorter hospital stay, and bet- 
er patient satisfaction for TRI relative to TFI [1–4] . Nonetheless, 
ata regarding differences in hospital cost incurred by PCI pa- 
ients according to PCI entry sites are limited. The few studies 
hat have examined this issue have been conducted in high and 
pper-middle -income countries and have suggested a cost sav- 
ng associated with TRI in comparison with TFI, mostly because of 
he reduction in length of hospital stay [5–7] . As healthcare prac- 
ice varies greatly by regions, it is unclear that the evidence from 
hese cost evaluations can be generalized to other countries, espe- 
ially those less economically developed for which there are lim- 
ted data, and potentially quite significant differences in standards 
f care. Investigating the cost saving for PCI procedures is also cru- 
ial in those countries as it can contribute to reducing the very 
igh economic burden of CHD patients and potentially reform the 
urrent PCI practices. Being aware of the cost differences in clini- 
al practice, cardiac interventionists can make their choices about 
ccess routes of PCI to reduce the financial burden on patients and 
ealthcare systems. 
In Asia, where CHD is the leading cause of death [ 8 , 9 ] the use of
CI for CHD patients is of growing interest in the region [10] . The
idespread use of TRI in PCI procedures has been documented in 
ecent studies [ 7 , 11 ], while the impact of PCI access sites on hos-
ital cost and procedural outcomes has not been adequately re- 
orted. This paper, uses data from the first PCI registry in Vietnam, 
ssessed in-hospital costs and post-procedural outcomes according 
o access sites and identified potential factors associated with in- 
ospital costs among patients undergoing PCI 
. Methods 
.1. Study population 
The study population was derived from a consecutive cohort of 
atients undergoing PCI from September 2017 to May 2018 at the 
ietnam National Heart Institute (VNHI), Hanoi, Vietnam. Full de- 
ails of the registry have been described elsewhere [ 12 , 13 ]. A total
f 1,022 patients were recruited in the registry from among 2,800 2 atients undergoing PCI at VNHI in the same period. Briefly, infor- 
ation on demography, cardiac status, procedure, and in-hospital 
ost of the participants was recorded by interviewing patients, ex- 
racting medical records, reading procedural discs and exploring 
he admission system. From the total pool of patients, those who 
nderwent > 1 PCI (n = 78) were excluded, as it is difficult to at-
ribute the bleeding events to a single procedure with certainty. 
atients with cardiogenic shock (n = 11) and those with missing 
ost data (n = 66) were also excluded as these groups were as- 
ociated with extremely high outlier costs or no information on 
otal cost, respectively. When > 1 entry location was used in one 
CI, the primary access site was the one allowing the completion 
f the procedure. After these exclusions, our study population con- 
isted of 868 patients with 694 TRIs and 174 TFIs. 
.2. In-hospital cost and outcomes 
The primary outcome was total in-hospital costs from the day 
f admission to discharge. Our cost data were obtained from the 
ospital admission system and classified under the following cat- 
gories: PCI costs (guide wire, IVUS, balloons and stents); medica- 
ion costs; examination/ laboratory costs; hospital bed costs; oper- 
tion costs (electrocardiogram in the ward and angiography); and 
edical supplies (syringes and needles). 
In-hospital outcomes were defined as major adverse car- 
iac events (MACE), major bleeding events and length of stay 
LOS, measured in days). MACE was a composite of in-hospital 
eath, myocardial infarction, and coronary revascularisation. Bleed- 
ng events were classified by the Bleeding Academic Research 
onsortium-BARC (2) indicating bleeding into five types according 
o clinical, laboratory, imaging evidence and health care required. 
ajor bleeding was defined as BARC 3. Medical records were ex- 
racted to document these in-hospital outcomes. 
.3. Statistical analysis 
Categorical variables (e.g., clinical, procedures, cost and out- 
omes) were presented as numbers and percentages, while con- 
inuous variables were expressed as mean ± SD unless otherwise 
pecified. Unlike the randomized clinical trials, the choice of access 
oint in real-world practice is often based on numerous factors, 
ncluding patients’ clinical characteristics and prognostic factors, 
herefore characteristics of study participants according to the two 
ccess sites were compared to see if there were any differences, 
sing chi-square or Fisher exact tests and Independent samples t- 
est as appropriate. Median in-hospital costs and LOS were com- 
ared between TRI and TFI with the Mann-Whitney U test, the un- 
djusted and adjusted differences were obtained by Median regres- 
ions. Characteristic variables with statistical significance (p-value 
 0.05) were selected for adjusting the cost differences. Logistic re- 
ression analyses were undertaken for two binary outcomes (ma- 
or bleeding and MACE). Costs were converted into US Dollars, 
ased on June 2019 exchange rates where 1USD = 23,350 Viet- 
amese Dong. These costs were then log transformed due to the 
ikely skew in cost data, and the normality of this logged data was 
xplored by both graphical and analytical methods such as skew- 
ess, kurtosis, box plot, Shapiro-Wilk and Kolmogorov-Smirnov test 
14] . Multiple linear regressions were performed to identify the 
nfluence of different independent variables on the independent 
ariable-log total in-hospital cost. Independent variables included 
ge (year, continuous), sex (male vs. female), level of support from 
ealth insurance ( > 80 and ≤80%), acute coronary syndrome (yes 
s. no), hypertension (yes vs. no), diabetes (yes vs. no), current 
moking (yes vs. no), prior stroke (yes vs. no), prior coronary artery 
ypass grafting (CABG) (yes vs. no), prior PCI (yes vs. no); trans- 
adial PCI (yes vs. no), left ventricular ejection fraction ( < 40% vs. 
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Table 1 
Clinical and procedural characteristics of the study population. 
TRI (n = 694) TFI (n = 174) P value 
Age (year), mean ± SD 68.3 ± 9.7 69.3 ± 10.6 0.209 a 
Male 469 (67.6) 117 (67.2) > 0.999 














BMI ≥ 23.0 kg/m 2 264 (38.0) 73 (42.0) 0.390 
Presentation 
ST-elevation myocardial infarction 93 (13.4) 18 (10.3) 0.341 
Non-ST-elevation myocardial infarction 105 (15.1) 24 (13.8) 0.746 
Unstable angina 165 (23.8) 42 (24.1) 0.999 
Non-acute coronary syndrome 331 (47.7) 90 (51.7) 0.386 
Medical history 
Hypertension 462 (66.6) 122 (70.1) 0.423 
Diabetes mellitus 191 (27.5) 59 (33.9) 0.116 
Hyperlipidaemia 209 (30.1) 62 (35.6) 0.189 
Current smoking 75 (10.8) 19 (10.9) > 0.999 
Prior cerebral vascular disease 94 (13.5) 25 (14.4) 0.874 
Prior peripheral vascular disease 4 (0.6) 2 (1.1) 0.761 
Previous CABG 4 (0.6) 5 (2.9) 0.024 
Previous PCI 218 (31.4) 75 (43.1) 0.005 
Tests prior to PCI 
Left ventricular ejection fraction < 40% 68 (11.1) 14 (8.9) 0.513 
Moderate to severe renal impairment b 12 (1.7) 6 (3.4) 0.268 
Procedural characteristics 
Left main disease 45 (6.5) 35 (20.1) < 0.001 
Restenotic lesions 30 (4.3) 11 (6.3) 0.478 
PCI with ≥ 2 lesions 49 (7.1) 11 (6.3) 0.860 
PCI with ≥ 2 stents 257 (37.0) 76 (43.7) 0.127 
Drug-eluting stent use 683 (100.0) 168 (100.0) _ 
Balloon only 7 (1.0) 2 (1.1) 0.871 
Intravascular ultrasound 28 (4.0) 12 (6.9) 0.13 
a Independent samples T test. 
b Creatinine > 200 μmol/L; Otherwise were Fisher exact or chi-square tests; TRI = Transradial intervention; 


















































40%), moderate to severe renal impairment (yes vs. no), intravas- 
ular ultrasound (yes vs. no), left main disease (yes vs. no), PCI 
ith ≥ 2 lesions (yes vs. no), PCI with ≥ 2 stents (yes vs. no), major 
leeding (yes vs. no), and MACE (yes vs. no). Variables with p < 0.1 
n univariate regression analyses were included in the multivari- 
ble regression model. To assess potential predictors of in-hospital 
osts percentage changes were computed by exponentiating un- 
tandardized coefficients and subtracting one from the resultant 
umber and multiplying by 100. Relative importance of possible 
redictors of total hospital costs was evaluated using standardised 
egression coefficients. Subgroup analyses according to the pres- 
nce or absence of acute coronary syndromes (ACS) were also con- 
ucted to evaluate cost and outcome differences All p-values were 
wo-tailed with statistical significance being defined as p ≤ 0.05. 
ll statistical analyses were performed in SPSS (SPSS Version 20.0 
or Windows; SPSS Inc., Chicago, IL). 
.4. Ethics approval 
The study received ethical approval from the Curtin Univer- 
ity Human Research Ethics Committee (HRE 2017-0378) and Viet- 
am National Heart Institute provided reciprocal approvals for the 
tudy to be conducted and data analysed in Australia. A Patient 
nformation Sheet was provided for every participant, which de- 
cribed clearly the purpose of the study, activities and rights of 
articipants. It was voluntary to participate in the study and it is 
he right of participants to decline their participation or withdraw 
rom the study via an ‘opt-out’ consent. The withdraw could oc- 
ur at any time without any consequence. Each participant was as- 
igned a unique ID which linked to the private information such as 
ame, age, address, and phone numbers for follow- ups. All infor- 3 ation that could be used to identify participants was coded and 
tored confidentially. 
.5. Role of the funding source 
The funding source had no role in either study design, data col- 
ection, data analysis or interpretation and drafting the report. The 
orresponding author have full access to all data obtained from the 
tudy and have the final responsibility for publication submission. 
. Results 
.1. Clinical and procedural characteristics 
Among the 868 patients in the eligible study population, TRI 
as the dominant access for PCI in our registry (694 patients, 
9.9%). Table 1 compares demographic, clinical and procedural 
haracteristics of TRI and TFI. Overall, the two target comparison 
roups had few differences in medical history and procedural char- 
cteristics. Patients undergoing TRI were relatively less likely to 
ave previous coronary revascularization such as PCI and CABG 
p = 0.024 and p = 0.005). They also tended to have less disease 
n the left main artery (p < 0.001). 
.2. In-hospital cost and outcomes 
The median total hospital costs were 4132 and 5910 USD for pa- 
ients undergoing TRI and TFI in our study (unadjusted cost differ- 
nce: -1778 USD, approximately 30%). After accounting for baseline 
ifferences between the two groups (i.e. history of CABG and PCI, 
nd left main disease), the adjusted difference was -1526.3 USD, 
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Table 2 
Hospital costs and clinical outcomes between transradial (TRI) and transfemoral (TFI) percutaneous coronary intervention (PCI). 
TRI (n = 694) TFI (n = 174) 
Unadjusted differences (95% 
CI) (TRI versus TFI) 
Adjusted differences d (95% 
CI) (TRI versus TFI) P value 
Hospital cost (USD c ), Median 
Total hospital cost 4132.0 5910.1 −1778.1 (-2253.3; -1302.8) −1526.3 (-1996.2; 
-1056.3) 
< 0.001 
Out of pockets 1093.4 1980.6 −887.2 (-1130.3; -644.3) −830.4 (-1075.7; -585.0) < 0.001 
Health insurance support 3047.3 3661.2 −613.9 (-723.9; -503.8) −506.1 (-649.7; -362.4) < 0.001 
PCI cost 3482.9 5077.8 −1594.9 (-2053.1; -1136.5) −1397.5 (-1875.7; -919.2) < 0.001 
Medication cost 37.6 56.2 −18.6 (-28.3; -9.0) −18.4 (-26.2; -10.5) < 0.001 
Examination/ laboratory cost 96.5 107.9 −11.4 (-22.0; -1.3) −12.2 (-24.1; -0.3) 0.020 
Operation cost 293.0 296.2 −3.2 (-5.0; -1.2) −2.9 (-4.7; -0.9) < 0.001 
Hospital bed cost 59.9 102.8 −42.9 (-56.9; -28.7) −38.8 (-50.5; -27.1) < 0.001 
Medical supplies cost 30.6 31.4 −0.8 (-1.7; -0.0) −0.7 (-1.3; -0.1) 0.011 
Length of stay (day), Median 4.0 6.0 −2.0 (-2.9; -1.0) −2.0 (-2.8; -1.2) < 0.001 
Major adverse cardiac events (MACE) b , n (%) 4 (0.6) 0 (0.0) _ _ 0.589 
Major bleeding, n (%) 5 (0.7) 14 (8.0) −7.3 (-11.4; -3.2) −7.2 (-11.4; -2.9) < 0.001 
b MACE was the composite of death, myocardial infarction, and coronary revascularisation. 
c One US dollar is approximately equivalent to 23,350 Vietnam dong (20 June 2019). 
d Factors adjusted for the difference: previous coronary artery bypass grafts; previous percutaneous coronary intervention; left main disease. 
Table 3 
Impact of clinical, procedural and outcomes on in-hospital total cost. 
Characteristics a 
Percentages changes of 
total hospital cost (%) Standardized Coefficients β P value 
Age (5-year increment) 0.7 0.084 0.003 
Hypertension 0.4 0.011 0.702 
Diabetes 1.9 0.052 0.066 
Prior CABG 9.5 0.056 0.048 
Transradial PCI −10.0 −0.252 < 0.0001 
Left main disease 7.1 0.121 < 0.0001 
PCI with ≥ 2 lesions 10.7 0.156 < 0.0001 
PCI with ≥ 2 stents 15.3 0.417 < 0.0001 
Major bleeding −0.2 −0.002 0.954 
CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention. 
a With the exception of age variable, all variables are dichotomous and the absence of each variable 

















































ndicating that the cost of TRI is lower than that for TFI by 25.8%
p < 0.001) ( Table 2 ). While health insurance contribution was 
igh (60-70%) in both groups, the out of pocket expenses of partici- 
ants were 1093 and 1980 USD in TRI and TFI groups, respectively. 
he majority of in-hospital cost was driven by the particular PCI 
ost (over 80%) in both groups ( Table 2 ). TFI was associated with
igher costs in all particular cost categories such as PCI cost, medi- 
ation cost, laboratory cost, hospital bed cost and medical supplies 
ost (p < 0.001). Additionally, patients undergoing TFI were also 
ore likely to have longer LOS, and procedural complications such 
s major bleeding (p < 0.001). 
.3. Impact of clinical, procedural and outcomes on in-hospital total 
ost 
Procedural characteristics had the largest impact on total hos- 
ital cost, including trans-radial PCI, left main disease, PCI with ≥
 lesions and PCI with ≥ 2 stents (the standardized coefficients 
ere -0.252; 0.121; 0.156; and 0.417, respectively) (all p < 0.05) 
 Table 3 ). Additionally, patient’s age and prior CABG also had an 
mpact on total in-hospital costs (p < 0.05). 
.4. Subgroup analyses 
Of 868 patients, the number of patients with ACS and without 
CS who underwent PCI was 447 and 421, respectively ( Table 4 ). 
esults of subgroup analyses by ACS status were consistent with 
hose obtained from the analysis of all subjects. Compared with 
atients undergoing PCI through TFI, those who received TRI con- 
umed lower in-hospital costs, had a shorter hospital stay and 4 xperienced less major bleeding in either ACS or non-ACS (all 
 < 0.05). 
. Discussion 
This study is the first to quantify in-hospital costs and out- 
omes between TRI and TFI in Vietnam. TRI was significantly asso- 
iated with a lower cost of 1526.3 USD than TFI (25.8%), a shorter 
ospital stay and less major bleeding post procedure. The find- 
ngs are important evidence in PCI cost saving, especially in this 
ower-middle-income country, where patients endure hardship for 
ealthcare expenses. The result of this study can also contribute 
o amending clinical practice guidelines and assisting clinicians in 
aking their decisions on the use of PCI. 
.1. In-hospital cost and post procedural outcomes according to the 
ntry sites 
Compared with TFI, the use of TRI in PCI practice has received 
ore support partly because it was shown to reduce the bleed- 
ng associated with access sites and PCI complications [ 1 , 15 , 16 ].
lthough few studies have investigated cost differences between 
wo different entry sites, among those reporting costs, similar re- 
ults were reported. Early previous findings reported that TRI was 
ssociated with significant reduction in total hospital costs, e.g., up 
o 15% reduction relative to TFI [ 17 , 18 ]. Recent data, both in coun-
ries where TFI has been the dominant access such as the USA, and 
ountries where TRI was more preferred such as China and UK, 
lso confirmed the favourable cost advantage of TRI relative to TFI 
 5–7 , 19 ]. Despite differences in the data analysis approach across 
H.T.T. Vu, R. Norman, N.M. Pham et al. The Lancet Regional Health - Western Pacific 9 (2021) 100116 
Table 4 
Cost and outcomes differences between ACS and non-ACS group. 
TRI TFI Unadjusted difference (95% CI) Adjusted difference d (95% CI) P value 
ACS (n = 447) 
Total hospital cost (USD c ) median 4407.5 5422.4 −1014.9 (-1619.5; -410.3) −1257.7 (-1833.6; -681.7) < 0.0001 
Length of stay (day), median 4.0 6.0 −2.0 (-2.9; -1.1) −1.0 (-1.9; -0.1) < 0.0001 
Major bleeding, n (%) 3 (0.8) 8 (9.5) −8.7 (-15.1; -2.4) −8.9 (-15.7; -2.1) < 0.0001 
MACE, n (%) 3 (0.8) 0 (0.0) _ _ > 0.9999 
Non-ACS (n = 421) 
Total hospital cost (USD c ) median 4006.9 6159.3 −2152.4 (-2839.1; -1465.7) −1965.2 (-2626.5; -1303.9) < 0.0001 
Length of stay (day), median 4.0 7.0 −3.0 (-3.9; -2.1) −2.0 (-2.9; -1.1) < 0.0001 
Major bleeding, n (%) 2 (0.6) 6 (6.7) −6.1 (-11.2; -0.8) −5.9 (-11.4; -0.5) 0.002 
MACE, n (%) 1 (0.3) 0 (0.0) _ _ > 0.9999 
ACS: acute coronary syndrome; MACE was the composite of death, myocardial infarction, and coronary revascularisation. 
c One US dollar is approximately equivalent to 23,350 Vietnam dong (20 June 2019). 
d Factors adjusted for the difference: previous coronary artery bypass grafts; previous percutaneous coronary intervention; left main dis- 
ease. 
Fig. 1. Cost reduction of trans-radial in total hospital cost. 









































tudies, our findings were concordant with these results, suggest- 
ng the finding to be robust. The difference in in-hospital costs for 
he TRI group in our study was among the highest, compared with 
ther studies in China and USA [5–7] ( Figure 1 ). The characteristics 
f the two access site groups might be part of the explanation for 
his difference. Unlike these previous studies, our TFI patient group 
as likely to have more stents per lesion than the TRI group, prob- 
bly due to more left main diseases in the former group. This dif- 
erence subsequently increased the procedure cost, the major com- 
onent of hospital cost. 
The health care system in Vietnam includes both public and pri- 
ate sectors and health care is not free for all people. Our study 
as conducted in a public hospital where health insurance can 
over some components of total expenses that patients incurred 
n hospital. While health insurance contributed a large proportion 
f hospital cost of all PCIs (60-70%), the cost difference in out of 
ocket expenditure was extremely significant in terms of the eco- 
omic burden on patients, especially given the average monthly in- 
ome per capita of Northern Vietnamese people was low (approx- 
mately 168 USD in 2016) [20] . Depending on the clinical presen- 
ation, diagnosis and prognosis of CHD patients, cardiologists will 
onsider the appropriate care and treatment methods, such as PCI 
r medical therapy. In some very high cost health care such as PCI, c  
5 he ability to pay might affect the treatment provided, especially 
n patients with low income and/or no health insurance. Therefore, 
dentifying the in-hospital costs of patients undergoing PCIs using 
he two access points is an important consideration for future im- 
lementing TRI programs. 
Regarding post-procedural outcomes in hospital of patients un- 
ergoing PCI, similar findings were found in our study. While the 
eduction advantage of TRI in bleeding complications was reported 
n most previous studies [ 5–7 , 16 , 21 ], significant reduction of car-
iovascular outcomes such as in-hospital mortality and MACE were 
lso found in TRI group [ 7 , 16 ]. Additionally, patients undergoing 
RI in India, China, Australia and USA were found to discharge ear- 
ier than their TFI counterparts (from 0.2 day to 2.3 days), which 
lso contribute to the cost reduction [ 5 , 7 , 16 , 21 ]. Thus, our findings
mpirically support the recommendations of recent guidelines on 
dopting TRI in clinical and add economic evidence to promote the 
se of this approach in the community practice [ 22 , 23 ]. 
.2. Factor associated with hospital cost of patients undergoing PCI 
Previous studies reported that the cost saving of TRI was re- 
ated strongly with a reduced LOS and/or a lower rate of post pro- 
edural bleeding complication [ 6 , 7 , 19 ]. Similar findings were found































































































n our study. Beside the main component of hospital cost (i.e. PCI 
ost), other cost differences were seen in terms of hospital bed 
osts, medication and laboratory tests, which indicated the signifi- 
ant contribution of LOS to the total hospital cost. Thus, to explore 
he potential effect of other factors associated with total hospital 
ost, we eliminated LOS in our analysis as LOS seemed to be af- 
ected by other factors such as post procedural complications. The 
esult revealed total hospital cost was likely to be driven mostly by 
rocedural characteristics, especially PCI with ≥ 2 stents and the 
CI access sites. This result reinforced the highest contribution of 
CI cost to total hospital costs observed in Table 2 . Findings from a
tudy in China also supported our study, indicating that total hos- 
ital cost differences of PCI patients were related mostly to proce- 
ural cost, e.g., vascular closure devices [7] , while two studies in 
SA indicated that the cost saving of TRI was found only in terms 
f post procedural costs [ 5 , 6 ]. This observation might be explained
y the differences in health care systems in Western and Asian 
ountries, which need to be investigated in further studies. Thus, 
ur study reported that the procedural factors such as number of 
tents per lesion ( ≥ 2), PCI access sites having the most impact 
n the in-hospital cost of patients undergoing PCI. By reporting 
his finding, we believe that our study made a significant impact 
n clinical practice of PCI in the country. Even though TRI is the 
urrent preferred approach, the valued cost saving of TRI relative 
o TFI was reported for the first time in a reliable study, which 
upports the use of this location access in PCI practice at VNHI. 
he interventionists and cardiologists might consider the result of 
his study in managing their practice at VNHI to provide the cost- 
ffective care for patients, especially the ones who have financial 
ardship or no health insurance. This strategy can also be followed 
t lower level hospitals in Vietnam given the training and educa- 
ional roles of VNHI. 
There are some limitations in our study. First, cost data were 
btained from the hospital admission system, which can reflect 
nly cost incurred by patients during hospitalization, but not in- 
irect costs such as food supplied or accommodation for the pa- 
ient’s families who came to care for the patient. Other costs prior 
o and after discharge was also not investigated. Second, despite 
djustment of the cost and outcome differences, selection bias can- 
ot be ruled out due to the nature of non-randomisation of ac- 
ess sites. In fact, most of the participants characteristics are sim- 
lar between the TRI and TFI group. Another concern is that our 
ata were only derived from the leading cardiac centre in Viet- 
am, where the highest technology might be applied, then findings 
ight not be considered as representative for the whole nation, 
ut provided important insight of PCI practices. More dedicated 
tudies should be conducted to give full insights of in-hospital cost 
or the PCI practices in Vietnam. 
. Conclusion 
Our study based on the first Vietnamese PCI registry provides 
n opportunity to understand current insights of in-hospital cost 
nd outcomes of patients undergoing PCI according to entry sites 
n Vietnam. TRI was the most preferred access site and overall, pa- 
ients undergoing TRI were associated with lower in-hospital costs, 
horter LOS and favourable post-procedural outcomes in compari- 
on with TFI. Procedural factors such as PCI with ≥2 stents and 
CI access sites had the most impact on in-hospital cost of PCI pa- 
ients. 
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